Hospitals to get direct shipments of COVID-19 antiviral drug remdesivir through HHS secured supply

June 29, 2020 / Mallory Hackett, Associate Editor

The Department of Health and Human Services has secured more than 500,000 treatment courses of the drug remdesivir to be purchased directly by hospitals through a new agreement with Gilead Sciences.

The agreement goes through September. The drug will be sent directly to hospitals based on state health department allocation data. Previously, the drug was sent to health departments to be delivered to hospitals, but the new protocol is aimed at streamlining the process, according to HHS.

Hospitals will receive the product at a price no higher than the wholesale acquisition price of approximately $3,200 per treatment course.

Shipments of remdesivir will occur every two weeks, according to the HHS. The shipments will be based upon hospitalization and inpatient data.


Mike Adams

Mike Adams is a medical device sales leader with extensive clinical experience in spine and biologics and a nationwide distribution network built over the last 10+ years in the industry. He has held various leadership positions in healthcare and device including Distributor Partner, Hospital COO and Spine VP of Sales. He currently leads the commercialization strategy for OrthoSpine Partners and is a Distributor Principal at Novel Medical. Because of his unique career path, Mike has the ability to see the healthcare business from multiple perspectives making him passionate about building strategic partnerships that help reduce overall costs, drive innovation, and cultivate growth for new markets.

Related Articles

Back to top button